| Literature DB >> 28438775 |
Gary A Abel1, Silvia C Mendonca2, Sean McPhail3, Yin Zhou2, Lucy Elliss-Brookes3, Georgios Lyratzopoulos4.
Abstract
BACKGROUND: Emergency diagnosis of cancer is common and aetiologically complex. The proportion of emergency presenters who have consulted previously with relevant symptoms is uncertain. AIM: To examine how many patients with cancer, who were diagnosed as emergencies, have had previous primary care consultations with relevant symptoms; and among those, to examine how many had multiple consultations. DESIGN ANDEntities:
Keywords: cancer; diagnosis; emergency; opportunities; primary care
Mesh:
Year: 2017 PMID: 28438775 PMCID: PMC5442953 DOI: 10.3399/bjgp17X690869
Source DB: PubMed Journal: Br J Gen Pract ISSN: 0960-1643 Impact factor: 5.386
Predictors of no prior GP consultation among emergency presenters (n = 4647)
| Brain | 173 | 80 | 46.2 | 1.84 (1.31 to 2.57) | 2.08 (1.47 to 2.94) | <0.001 |
| Renal | 102 | 45 | 44.1 | 1.68 (1.11 to 2.56) | 1.71 (1.12 to 2.62) | |
| Endometrial | 57 | 22 | 38.6 | 1.34 (0.77 to 2.34) | 1.54 (0.88 to 2.72) | |
| Breast | 156 | 54 | 34.6 | 1.13 (0.79 to 1.62) | 1.42 (0.97 to 2.07) | |
| Rectal | 235 | 93 | 39.6 | 1.40 (1.03 to 1.89) | 1.37 (1.01 to 1.86) | |
| Oesophageal | 86 | 33 | 38.4 | 1.33 (0.84 to 2.11) | 1.16 (0.73 to 1.85) | |
| Stomach | 116 | 43 | 37.1 | 1.26 (0.84 to 1.89) | 1.11 (0.74 to 1.67) | |
| Lung | 389 | 134 | 34.4 | 1.12 (0.86 to 1.45) | 1.11 (0.85 to 1.44) | |
| Colon | 752 | 240 | 31.9 | Reference | Reference | |
| Bladder | 264 | 92 | 34.8 | 1.14 (0.85 to 1.53) | 0.97 (0.72 to 1.31) | |
| Prostate | 209 | 73 | 34.9 | 1.15 (0.83 to 1.58) | 0.93 (0.67 to 1.30) | |
| Leukaemia | 519 | 130 | 25.0 | 0.71 (0.55 to 0.92) | 0.81 (0.62 to 1.05) | |
| Multiple myeloma | 513 | 119 | 23.2 | 0.64 (0.50 to 0.83) | 0.66 (0.51 to 0.86) | |
| Non-Hodgkin lymphoma | 514 | 112 | 21.8 | 0.59 (0.46 to 0.77) | 0.63 (0.48 to 0.81) | |
| Pancreatic | 118 | 20 | 16.9 | 0.44 (0.26 to 0.72) | 0.45 (0.27 to 0.74) | |
| Ovarian | 324 | 44 | 13.6 | 0.34 (0.24 to 0.48) | 0.41 (0.29 to 0.60) | |
| Hodgkin lymphoma | 59 | 7 | 11.9 | 0.29 (0.13 to 0.64) | 0.35 (0.15 to 0.80) | |
| Mesothelioma | 61 | 8 | 13.1 | 0.32 (0.15 to 0.69) | 0.30 (0.14 to 0.64) | |
|
| ||||||
| Male | 2526 | 819 | 32.4 | Reference | Reference | <0.001 |
| Female | 2121 | 530 | 25.0 | 0.69 (0.61 to 0.79) | 0.74 (0.64 to 0.86) | |
|
| ||||||
| 16–24 | 96 | 16 | 16.7 | 0.46 (0.27 to 0.80) | 0.48 (0.27 to 0.86) | <0.001 |
| 25–34 | 123 | 37 | 30.1 | 0.99 (0.67 to 1.49) | 1.01 (0.66 to 1.55) | |
| 35–44 | 235 | 52 | 22.1 | 0.66 (0.47 to 0.91) | 0.67 (0.48 to 0.95) | |
| 45–54 | 539 | 138 | 25.6 | 0.80 (0.64 to 1.00) | 0.78 (0.62 to 0.99) | |
| 55–64 | 1153 | 312 | 27.1 | 0.86 (0.72 to 1.02) | 0.85 (0.71 to 1.01) | |
| 65–74 | 1441 | 435 | 30.2 | Reference | Reference | |
| 75–84 | 876 | 279 | 31.8 | 1.08 (0.90 to 1.30) | 1.07 (0.89 to 1.29) | |
| ≥85 | 184 | 80 | 43.5 | 1.78 (1.30 to 2.43) | 1.64 (1.19 to 2.26) | |
|
| ||||||
| White | 4431 | 1288 | 29.1 | Reference | Reference | 0.94 |
| Other | 216 | 61 | 28.2 | 0.77 (0.50 to 1.21) | 0.99 (0.72 to 1.36) | |
|
| ||||||
| Affluent | 987 | 248 | 25.1 | Reference | Reference | 0.001 |
| Deprivation group 2 | 1023 | 288 | 28.2 | 1.17 (0.96 to 1.42) | 1.15 (0.93 to 1.40) | |
| Deprivation group 3 | 959 | 280 | 29.2 | 1.23 (1.01 to 1.50) | 1.22 (0.99 to 1.50) | |
| Deprivation group 4 | 858 | 247 | 28.8 | 1.20 (0.98 to 1.48) | 1.19 (0.96 to 1.47) | |
| Most deprived | 820 | 286 | 34.9 | 1.60 (1.30 to 1.96) | 1.56 (1.26 to 1.92) | |
|
| ||||||
Adjusted for cancer site, age, sex, ethnic group, and deprivation group.
For adjusted OR. OR = odds ratio.
Figure 1.
Figure 2.
Cancer site and sociodemographic predictors of at least three prior GP consultations — among emergency presenters who had consulted at least once (n = 3298)
| Multiple myeloma | 394 | 222 | 56.3 | 1.84 (1.41 to 2.40) | 1.81 (1.38 to 2.37) | <0.001 |
| Non-Hodgkin lymphoma | 402 | 192 | 47.8 | 1.30 (1.00 to 1.70) | 1.19 (0.91 to 1.56) | |
| Lung | 255 | 114 | 44.7 | 1.15 (0.85 to 1.56) | 1.14 (0.84 to 1.55) | |
| Prostate | 136 | 50 | 36.8 | 0.83 (0.56 to 1.23) | 1.05 (0.70 to 1.57) | |
| Colon | 512 | 211 | 41.2 | Reference | Reference | |
| Rectal | 142 | 58 | 40.8 | 0.98 (0.67 to 1.44) | 0.98 (0.67 to 1.44) | |
| Stomach | 73 | 27 | 37.0 | 0.84 (0.50 to 1.39) | 0.96 (0.57 to 1.61) | |
| Ovarian | 280 | 127 | 45.4 | 1.18 (0.88 to 1.59) | 0.95 (0.70 to 1.29) | |
| Brain | 93 | 43 | 46.2 | 1.23 (0.79 to 1.91) | 0.93 (0.59 to 1.47) | |
| Hodgkin lymphoma | 52 | 26 | 50.0 | 1.43 (0.81 to 2.53) | 0.87 (0.48 to 1.60) | |
| Endometrial | 35 | 15 | 42.9 | 1.07 (0.54 to 2.14) | 0.85 (0.42 to 1.72) | |
| Renal | 57 | 20 | 35.1 | 0.77 (0.44 to 1.37) | 0.80 (0.45 to 1.42) | |
| Pancreatic | 98 | 35 | 35.7 | 0.79 (0.51 to 1.24) | 0.77 (0.49 to 1.21) | |
| Oesophageal | 53 | 16 | 30.2 | 0.62 (0.33 to 1.14) | 0.69 (0.37 to 1.29) | |
| Bladder | 172 | 44 | 25.6 | 0.49 (0.33 to 0.72) | 0.61 (0.41 to 0.90) | |
| Mesothelioma | 53 | 14 | 26.4 | 0.51 (0.27 to 0.97) | 0.58 (0.31 to 1.11) | |
| Breast | 102 | 32 | 31.4 | 0.65 (0.41 to 1.03) | 0.44 (0.27 to 0.71) | |
| Leukaemia | 389 | 110 | 28.3 | 0.56 (0.42 to 0.75) | 0.41 (0.30 to 0.55) | |
|
| ||||||
| Male | 1707 | 644 | 37.7 | Reference | Reference | <0.001 |
| Female | 1591 | 712 | 44.8 | 1.34 (1.16 to 1.54) | 1.35 (1.15 to 1.59) | |
|
| ||||||
| <0.001 | ||||||
| 16–24 | 80 | 38 | 47.5 | 1.45 (0.92 to 2.29) | 2.22 (1.34 to 3.66) | |
| 25–34 | 86 | 43 | 50 | 1.60 (1.03 to 2.49) | 2.04 (1.27 to 3.29) | |
| 35–44 | 183 | 104 | 56.8 | 2.11 (1.53 to 2.90) | 2.71 (1.92 to 3.81) | |
| 45–54 | 401 | 188 | 46.9 | 1.41 (1.12 to 1.78) | 1.51 (1.18 to 1.93) | |
| 55–64 | 841 | 376 | 44.7 | 1.29 (1.07 to 1.56) | 1.30 (1.07 to 1.58) | |
| 65–74 | 1006 | 387 | 38.5 | Reference | Reference | |
| 75–84 | 597 | 192 | 32.2 | 0.76 (0.61 to 0.94) | 0.78 (0.62 to 0.97) | |
| ≥85 | 104 | 28 | 26.9 | 0.59 (0.38 to 0.93) | 0.67 (0.42 to 1.06) | |
|
| ||||||
| White | 3143 | 1275 | 40.6 | Reference | Reference | 0.017 |
| Other | 155 | 81 | 52.3 | 1.60 (1.16 to 2.22) | 1.52 (1.08 to 2.13) | |
|
| ||||||
| Affluent | 739 | 316 | 42.8 | Reference | Reference | 0.380 |
| Deprivation group 2 | 735 | 300 | 40.8 | 0.92 (0.75 to 1.14) | 0.94 (0.76 to 1.16) | |
| Deprivation group 3 | 679 | 253 | 37.3 | 0.79 (0.64 to 0.98) | 0.80 (0.64 to 1.00) | |
| Deprivation group 4 | 611 | 254 | 41.6 | 0.95 (0.77 to 1.18) | 0.94 (0.75 to 1.18) | |
| Most deprived | 534 | 233 | 43.6 | 1.04 (0.83 to 1.30) | 0.95 (0.75 to 1.20) | |
|
| ||||||
Adjusted for cancer site, age, sex, ethnic group, and deprivation group.
For adjusted OR. OR = odds ratio.
Figure 3.
Figure 4.
| Linkage was carried out previously by the Public Health England National Cancer Intelligence Network to support public reporting of data on cancer patient experience. |
Quality Health. 2014 National Cancer Patient Experience Survey National Report and Related Data. https://www.quality-health.co.uk/resources/surveys/national-cancer-experience-survey/2014-national-cancer-patient-experience-survey/2014-national-cancer-patient-experience-survey-national-reports (accessed 20 Mar 2017).
| Lung | 8.4 | 26.6 | 3.18 |
| Pancreatic | 2.5 | 7.0 | 2.75 |
| Stomach | 2.5 | 4.3 | 1.70 |
| Oesophageal | 1.9 | 3.0 | 1.64 |
| Renal | 2.2 | 3.4 | 1.55 |
| Prostate | 4.5 | 6.5 | 1.45 |
| Brain | 3.7 | 5.2 | 1.39 |
| Mesothelioma | 1.3 | 1.6 | 1.21 |
| Breast | 3.4 | 3.8 | 1.13 |
| Endometrial | 1.2 | 1.1 | 0.91 |
| Colon | 16.2 | 13.2 | 0.81 |
| Rectal | 5.1 | 3.5 | 0.69 |
| Bladder | 5.7 | 3.4 | 0.60 |
| Ovarian | 7.0 | 3.7 | 0.53 |
| Non-Hodgkin lymphoma | 11.1 | 5.5 | 0.49 |
| Leukaemia | 11.2 | 4.9 | 0.44 |
| Hodgkin lymphoma | 1.3 | 0.5 | 0.40 |
| Multiple myeloma | 11.0 | 2.9 | 0.26 |
|
| |||
| Male | 54.4 | 53.4 | 0.98 |
| Female | 45.6 | 46.6 | 1.02 |
|
| |||
| 16–24 | 2.1 | 1.7 | 0.33 |
| 25–34 | 2.6 | 0.9 | 0.45 |
| 35–44 | 5.1 | 2.2 | 0.49 |
| 45–54 | 11.6 | 5.6 | 0.57 |
| 55–64 | 24.8 | 14.0 | 0.75 |
| 65–74 | 31.0 | 23.3 | 0.76 |
| 75–84 | 18.9 | 32.5 | 1.74 |
| ≥85 | 4.0 | 19.8 | 4.91 |
|
| |||
| Least deprived | 21.2 | 16.1 | 0.78 |
| Deprivation group 2 | 22.0 | 19.4 | 0.83 |
| Deprivation group 3 | 20.6 | 20.8 | 1.00 |
| Deprivation group 4 | 18.5 | 21.6 | 1.20 |
| Most deprived | 17.6 | 22.0 | 1.27 |
The stratification weights are standardised so that values >1 mean the emergency presentation of a type of cancer is under-represented in the English Cancer Patient Experience Survey (CPES) (and vice versa for values <1). These weights can be conceptualised as indicating the number of incident patients with cancer who present as emergencies in the population represented by each emergency presenter in the analysis sample.
These are the CPES 2010 responders who were diagnosed through emergency presentation.
The weights are calculated as follows:
The number was counted of CPES responders flagged as emergency presenters in the linked Routes to Diagnosis (RTD) 2006–2010 dataset for each cancer by sex, by age group, by deprivation strata (a total of 1440 strata).
The number was counted of emergency presenters in the population-based RTD dataset for each cancer by sex, by age group, by deprivation strata (a total of 1440 strata).
Where the number was zero in CPES but not in RTD, strata were merged across all deprivation groups (of responders with the same cancer diagnosis, sex, and age group).
After merging on deprivation there were still 46 cancer by sex by age strata with zero count in CPES and non-zero count in RTD. These strata were merged such that a stratum containing zero count in CPES was merged with the stratum of the most populous adjacent age group (of responders with the same sex and cancer diagnosis).
The weights for each of the 786 final strata were calculated by dividing the number of cases in the RTD dataset by the number of responders. The resulting weights were applied to each responder in the strata.
The weights were then normalised such that the mean weight among the analysis sample was = 1.
|
|
| ||||
|---|---|---|---|---|---|
| Brain | 2.08 (1.47 to 2.94) | 1.17 (0.64 to 2.15) | Multiple myeloma | 1.81 (1.38 to 2.37) | 1.44 (0.97 to 2.12) |
| Renal | 1.71 (1.12 to 2.62) | 0.88 (0.43 to 1.81) | Non-Hodgkin lymphoma | 1.19 (0.91 to 1.56) | 1.55 (1.04 to 2.32) |
| Endometrial | 1.54 (0.88 to 2.72) | 0.79 (0.29 to 2.15) | Lung | 1.14 (0.84 to 1.55) | 0.96 (0.63 to 1.48) |
| Breast | 1.42 (0.97 to 2.07) | 1.16 (0.59 to 2.29) | Prostate | 1.05 (0.70 to 1.57) | 0.92 (0.52 to 1.60) |
| Rectal | 1.37 (1.01 to 1.86) | 1.30 (0.85 to 1.97) | Colon | Reference | Reference |
|
| |||||
| Oesophageal | 1.16 (0.73 to 1.85) | 0.70 (0.37 to 1.33) | Rectal | 0.98 (0.67 to 1.44) | 1.03 (0.60 to 1.77) |
| Stomach | 1.11 (0.74 to 1.67) | 0.99 (0.54 to 1.81) | Stomach | 0.96 (0.57 to 1.61) | 1.17 (0.55 to 2.48) |
| Lung | 1.11 (0.85 to 1.44) | 1.10 (0.71 to 1.71) | Ovarian | 0.95 (0.70 to 1.29) | 1.36 (0.75 to 2.46) |
| Colon | Reference | Reference | Brain | 0.93 (0.59 to 1.47) | 0.94 (0.43 to 2.04) |
| Bladder | 0.97 (0.72 to 1.31) | 0.73 (0.47 to 1.11) | Hodgkin lymphoma | 0.87 (0.48 to 1.60) | 1.03 (0.43 to 2.49) |
| Prostate | 0.93 (0.67 to 1.30) | 0.94 (0.57 to 1.55) | Endometrial | 0.85 (0.42 to 1.72) | 0.67 (0.23 to 1.96) |
| Leukaemia | 0.81 (0.62 to 1.05) | 0.69 (0.40 to 1.17) | Renal | 0.80 (0.45 to 1.42) | 0.67 (0.31 to 1.48) |
| Multiple myeloma | 0.66 (0.51 to 0.86) | 0.80 (0.49 to 1.29) | Pancreatic | 0.77 (0.49 to 1.21) | 0.88 (0.45 to 1.70) |
| Non-Hodgkin lymphoma | 0.63 (0.48 to 0.81) | 0.51 (0.35 to 0.74) | Oesophageal | 0.69 (0.37 to 1.29) | 0.71 (0.32 to 1.55) |
| Pancreatic | 0.45 (0.27 to 0.74) | 0.35 (0.16 to 0.75) | Bladder | 0.61 (0.41 to 0.90) | 0.62 (0.36 to 1.05) |
| Ovarian | 0.41 (0.29 to 0.60) | 0.21 (0.12 to 0.36) | Mesothelioma | 0.58 (0.31 to 1.11) | 0.47 (0.21 to 1.05) |
| Hodgkin lymphoma | 0.35 (0.15 to 0.80) | 0.21 (0.08 to 0.55) | Breast | 0.44 (0.27 to 0.71) | 0.41 (0.20 to 0.85) |
| Mesothelioma | 0.30 (0.14 to 0.64) | 0.43 (0.12 to 1.49) | Leukaemia | 0.41 (0.30 to 0.55) | 0.45 (0.26 to 0.79) |
|
| |||||
| Male | Reference | Reference | Male | Reference | Reference |
| Female | 0.74 (0.64 to 0.86) | 0.83 (0.61 to 1.13) | Female | 1.35 (1.15 to 1.59) | 1.33 (0.99 to 1.79) |
|
| |||||
| 16–24 | 0.48 (0.27 to 0.86) | 0.49 (0.24 to 1.03) | 16–24 | 2.22 (1.34 to 3.66) | 2.47 (1.29 to 4.73) |
| 25–34 | 1.01 (0.66 to 1.55) | 0.96 (0.55 to 1.68) | 25–34 | 2.04 (1.27 to 3.29) | 2.24 (1.17 to 4.28) |
| 35–44 | 0.67 (0.48 to 0.95) | 0.64 (0.38 to 1.08) | 35–44 | 2.71 (1.92 to 3.81) | 1.25 (0.67 to 2.33) |
| 45–54 | 0.78 (0.62 to 0.99) | 0.79 (0.55 to 1.14) | 45–54 | 1.51 (1.18 to 1.93) | 1.40 (0.93 to 2.12) |
| 55–64 | 0.85 (0.71 to 1.01) | 0.84 (0.66 to 1.07) | 55–64 | 1.30 (1.07 to 1.58) | 1.39 (1.05 to 1.82) |
| 65–74 | Reference | Reference | 65–74 | Reference | Reference |
| 75–84 | 1.07 (0.89 to 1.29) | 1.02 (0.78 to 1.35) | 75–84 | 0.78 (0.62 to 0.97) | 0.73 (0.53 to 1.02) |
| ≥85 | 1.64 (1.19 to 2.26) | 1.49 (0.85 to 2.60) | ≥85 | 0.67 (0.42 to 1.06) | 0.54 (0.30 to 0.98) |
|
| |||||
| White | Reference | Reference | White | Reference | Reference |
| Other | 0.99 (0.72 to 1.36) | 0.91 (0.58 to 1.46) | Other | 1.52 (1.08 to 2.13) | 1.54 (0.90 to 2.64) |
|
| |||||
| Affluent | Reference | Reference | Affluent | Reference | Reference |
| Deprivation group 2 | 1.15 (0.93 to 1.40) | 1.19 (0.83 to 1.71) | Deprivation group 2 | 0.94 (0.76 to 1.16) | 1.03 (0.70 to 1.51) |
| Deprivation group 3 | 1.22 (0.99 to 1.50) | 1.49 (0.99 to 2.25) | Deprivation group 3 | 0.80 (0.64 to 1.00) | 0.70 (0.48 to 1.03) |
| Deprivation group 4 | 1.19 (0.96 to 1.47) | 1.28 (0.86 to 1.89) | Deprivation group 4 | 0.94 (0.75 to 1.18) | 1.24 (0.82 to 1.88) |
| Most deprived | 1.56 (1.26 to 1.92) | 1.43 (0.94 to 2.20) | Most deprived | 0.95 (0.75 to 1.20) | 0.81 (0.54 to 1.21) |
Spearman correlation coefficients for OR for cancer diagnosis between weighted and unweighted = 0.79 for ‘no prior consultation’ and = 0.83 for three or more prior GP consultations. Note: The primary interest is in comparing point estimates obtained from the main and the sensitivity analysis, rather than CI and P-values, as by nature the use of weights increases standard errors.